NANOSPRESSO is a healthcare project led by UMC Utrecht in the Netherlands, aiming to make personalised medicine more accessible. By using advanced microfluidic technology, the project enables hospitals to produce customised nanomedicines locally, providing advanced treatments for patients with rare diseases.
NANOSPRESSO unites experts from across Europe—including scientists, hospitals, biotech companies, and patient organisations—to ensure these treatments are safe, effective, and available to those who need them most. This collaboration aims to improve healthcare by making personalised treatments affordable and accessible.
NANOSPRESSO is an innovative project coordinated by UMC Utrecht (Netherlands) and funded by the Dutch Research Agenda (NWA)
NANOSPRESSO is a prime example of a Dutch-led initiative that thrives on European collaboration
The project brings together a wide array of stakeholders across the entire value chain, from research and development to clinical application. The consortium includes universities, research institutes, hospitals, biotech companies, and SMEs, all working in harmony to transform this ambitious idea into a real-world solution.
With over 10 partners, including universities like UMC Utrecht, research institutes like SINTEF (Norway), companies such as Lipoid GmbH (Germany), and international think tanks like the European Technology Platfom on Nanomedicine (ETPN, France), the project benefits from a rich combination of local and international expertise. Each partner brings unique knowledge, ensuring that NANOSPRESSO can navigate every stage of development—from technological innovation to patient care.
Project Coordinator
Prof. Dr. Raymond Schiffelers
Professor of Nanomedicine – UMC Utrecht
Short bio: Professor Raymond Schiffelers, a leading expert in nanomedicine, is the coordinator of the groundbreaking Nanospresso-NL project. With a rich academic background in Bio-Pharmaceutical Sciences and Medical Microbiology, his research has driven advancements in targeted drug delivery systems, from liposomal targeting to siRNA delivery and extracellular vesicles. As Professor of Nanomedicine at University Medical Center Utrecht, he leads innovative research into bio-inspired and synthetic drug delivery systems aimed at personalized medicine. In addition to his academic role, Prof. Schiffelers has successfully coordinated major European projects such as B-SMART and EXPERT under H2020, and now leads Nanospresso-NL, focused on bedside production of nucleic acid nanomedicines. He also serves as Vice President of Preclinical R&D at Nanocell Therapeutics, reflecting his active contribution to bridging academia and industry. Furthermore, he is the Chair of the European Technology Platform on Nanomedicine (ETPN) and an editor for several high-impact journals.
Work Package Leaders
UMC Utrecht (Netherlands)
The project coordinator, responsible for overall leadership and management, and leading WP1 on microfluidic technologies. With expertise in microfluidics for nanomedicine production, UMC Utrecht drives the technological innovation central to the project.
SINTEF (Norway)
Leading WP2, SINTEF ensures high standards of quality control for nucleic acid-based nanomedicines. Their specialization in advanced characterization techniques guarantees the safety and efficacy of the developed therapies.
Lipoid GmbH (Germany)
Leading WP3, Lipoid focuses on developing lipid nanoparticles for optimal drug delivery. As pioneers in lipid-based delivery systems, they contribute crucial expertise to make nucleic acid therapies viable.
ETPN (Europe)
Leading WP6 on communication and dissemination, ensuring that the project’s outcomes reach key stakeholders and the broader public. The European Technology Platform on Nanomedicine facilitates strategic thinking and clinical translation of innovative nanomedicine projects across Europe.
Involved Partners by activity
Industry
Clinical
Academic/Research Institutes
The Value Chain of Collaboration
NANOSPRESSO involves every key stakeholder in the value chain, ensuring that the project’s ambitious goals translate into real-world success. From scientific research and technological development to clinical trials and patient applications, each partner plays a vital role in advancing the project:
Researchers and universities contribute cutting-edge knowledge in nanomedicine and microfluidics.
Hospitals like UMC Utrecht provide clinical insights and trial capacities, ensuring the innovations address real patient needs.
Biotech companies like Lipoid GmbH develop advanced delivery systems that make nucleic acid therapies viable.
Regulators and legal experts ensure NANOSPRESSO aligns with European health and safety standards, paving the way for future commercialization.
Patient organisations ensure that the technology is developed with patients in mind, from the earliest stages of research to its final application.
This comprehensive collaboration ensures that NANOSPRESSO's vision—personalised nanomedicines produced locally in hospitals—is realised in a way that benefits all stakeholders, especially patients with rare diseases.
Dive into the NANOSPRESSO World with Our Interactive Map
Explore our interactive map to discover each of NANOSPRESSO’s partners. Hover over the dots to learn how each organization contributes its unique expertise to the project’s success, and see how Dutch leadership combined with European collaboration creates a powerful network. You can also click on a dot for more details about each partner.
To navigate the map, click and drag to move around, and use the plus and minus buttons to zoom in and out.
Our Collective Goal
The goal of NANOSPRESSO is to transform the healthcare landscape by making personalised nanomedicines both accessible and affordable, thereby reducing health disparities. By engaging a diverse range of stakeholders—from scientists to clinicians, manufacturers to regulators—we ensure that the technology we develop is robust, scalable, and ready to improve patient care across Europe and beyond. Our collaborative, multidisciplinary approach is designed to democratise access to advanced treatments, especially for patients with rare diseases who often lack effective therapeutic options. By focusing on reducing barriers to access, we aim to improve the quality of life for patients and contribute to more equitable healthcare systems.
Wanna get involved? We're going to need you to help make this ambitious project a success.
When submitting this form, I agree to share the entered data solely for the purpose of receiving the NANOSPRESSO's newsletter, in accordance with the Personal Data Protection Law. This site is protected by reCAPTCHA, and Google's Privacy Policy and Terms of Service apply.
